PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

The UPC’s first decision on infringement by equivalence (Plant-e v Bioo, UPC_CFI_239/2023)

  • Sector: Chemistry
  • 28th February 2025
 

Originally posted on IPKat.

In Plant-e v Bioo the UPC provided its first decision addressing the doctrine of equivalents in patent infringement proceedings (UPC_CFI_239/2023). The Local Division of the Hague set out a novel four-part test for assessing equivalence drawn from various national jurisdictions. The test appears relatively patentee-friendly, with the Local Division finding infringement of the claims despite the alleged infringement lacking explicit features of the invention as defined by the claims.

Legal background: Equivalence around Europe

The Unified Patent Court Agreement (UPCA) contains no specific provisions on the doctrine of equivalence. However, the Local Division of the UPC in this case found that Article 2 of the Protocol on the interpretation of Article 69 EPC makes it clear that equivalence should be considered when assessing the scope of protection of a European patent: “For the purpose of determining the extent of protection conferred by a European patent, due account shall be taken of any element which is equivalent to an element specified in the claims.” Beyond this high-level guidance from Article 2 of the Protocol, the UPC faces the challenge of developing its own approach to assessing infringement by equivalence. 

Case details: Plant-based fuel cells 

The dispute in UPC_CFI_239/2023 concerned EP2137782, owned by Plant-e Knowledge B.V., relating to a device and method for converting light energy into electrical energy using plants in microbial fuel cells (P-MFCs). The patent claimed a method requiring a living plant to be located in an anode compartment of the fuel cell, with micro-organisms living around the plant’s root zone. Plante-e brought an infringement action against Arkyne Technologies SL (aka Bioo). Bioo counterclaimed for revocation. The case was heard by the Local Division of the UPC in The Hague. The panel of judges comprised Presiding Judge Edger Brinkman (Netherlands), Legally qualified judge Samuel Granata (Belgium), Technically qualified judge Simon Walker and Judge-rapporteur Margot Kokke. 

The patent in question (EP2137782) particularly related to devices and methods of generating electricity from living plants using microbial fuel cells (MFCs). MFCs using microorganisms to convert organic compounds into electrical energy were known in the art. However, these conventional MFCs required external supply of organic material as fuel, creating sustainability issues. EP2137782 purported to solves this problem by incorporating a living plant directly into the MFC system. The plant converts light energy into organic material through photosynthesis. This organic material is then released by the roots into an anode compartment containing special “anodophilic” microorganisms. These microorganisms oxidize the organic material from the plant, generating electrons that are collected at the anode to produce electrical energy.

The patent claimed a device comprising a reactor having an anode compartment and cathode compartment, the anode compartment containing: a) an anodophilic microorganism capable of oxidizing an electron donor compound b) a living plant capable of converting light energy by photosynthesis into the electron donor compound, wherein “the root zone of the plant is essentially placed in the anodic material”. The patent was granted in 2017 and, notably, no opposition was filed at the EPO. 

 Plant-e alleged that Bioo’s products, in particular the “Bioo Panel” containing a two-compartment system with plants separated from the anode, infringed the patent. The Bioo Panel is a device for generating electricity using plants and soil. The panel consists of two compartments assembled in a single device. The upper compartment contains soil and optionally plants that grow naturally in the installation environment. The lower compartment contains what Bioo terms a “biological battery”, comprising an anode and cathode separated by soil. Rather than having the plant roots directly in contact with the anode (as in Plant-e’s patent), the two compartments are separated by a filter. However, the compartments are connected such that rainwater and irrigation can leach nutrients and microorganisms from the soil in the upper compartment through to the lower compartment containing the anode. 

The issue in this case was whether the Bioo panel two-compartment design, which deliberately avoided direct contact between plant roots and the anode, nonetheless infringed Plant-e’s patent claims requiring the “root zone of the plant to be essentially placed in the anodic material.” Bioo argued that its design was specifically developed to avoid the problems that occur when roots directly contact the anode, such as damage to the anode and disruption of the anaerobic conditions required for electricity generation. Indeed, Bioo had filed its own patent application (WO 2022/058500) describing these advantages of its two-compartment design.

The UPC’s 4-question approach to equivalence

The UPC had to consider whether, despite these deliberate design choices to separate the roots from the anode, the Bioo Panel still fell within the scope of Plant-e’s patent under the doctrine of equivalents. Critical to this assessment was whether organic material produced by the plants in the upper compartment could still reach the anode compartment to fuel electricity generation, even without direct root contact. 

The UPC faces an interesting challenge in developing its approach to equivalence. Whilst Article 2 of the Protocol to Article 69 EPC requires equivalents to be considered, it provides no guidance on how to assess them. The court therefore needed to craft its own test. The court proposed a novel four-part test. According to the decision, “the test is based on the case law in various national jurisdictions, as proposed by both parties in this case” (para. 88). Under this new test, a variation is deemed equivalent if all four questions are answered affirmatively:

“A variation is equivalent to an element specified in the claim if the following four questions are answered in the affirmative: 

i. Technical equivalence: does the variation solve (essentially) the same problem that the patented invention solves and performs (essentially) the same function in this context? 

ii. Fair protection for patentee: is extending protection proportionate to fair protection?

iii. Reasonable legal certainty: does the skilled person understand from the patent that the scope is broader than literally claimed? 

iv. Is the allegedly infringing product novel and inventive over the prior art?“

Applying its new test, the court found that whilst Bioo’s two-compartment system did not literally infringe as the plant was not in the anode compartment. However, the Local Division found that the alleged infringement was nonetheless equivalent. 

i. Technical equivalence: does the variation solve (essentially) the same problem that the patented invention solves and performs (essentially) the same function in this context? 

The Local Division found that the Bioo Panel was technically equivalent to the patented invention because it solved the same problem and performs the same function, i.e. using a plant as part of the reactor to provide organic material for generating electricity, making the device substantially independent of external fuel. Whilst the Bioo Panel used a different two-compartment setup, the Local Division deemed this difference immaterial since it didn’t affect the plant’s core function. For the Local Division, based on the evidence submitted, despite the different physical configuration of the device, the underlying technical solution remained the same. The Local Division therefore answered “yes” to this question. 

ii. Fair protection for patentee: is extending protection proportionate to fair protection?

The Local Division also found that extending the scope protection of the patent through equivalence to cover the Bioo Panel was proportionate and fair. The Local Division particularly found that Plant-e had made a significant contribution to the field by creating “a new category of microbial fuel cells, by introducing a plant into the device/reactor and to obtain electricity from organic material originating from the photosynthesis by that plant and thus from light energy” (para. 98). Given this substantial contribution, the Local Division deemed “a fairly broad scope of protection” appropriate, especially since the Bioo Panel implemented “exactly that principle” (para. 98) and the modification represented by the Bioo Panel would be obvious to a skilled person in view of the disclosure in the patent. 

iii. Reasonable legal certainty: does the skilled person understand from the patent that the scope is broader than literally claimed? 

In their answer to the third question, the Local Division found that the requirement of legal certainty was met because “the skilled person understands that the patent claim leaves room for equivalents because the teaching of the patent is (clearly) broader than the wording of the claim and there is, still in the eyes of the skilled person, no good reason to limit the scope of protection of the claim to a (method using a) device as claimed” (para. 100). Specifically, the court determined that “[t]he teaching of the patent is to add a plant to a MFC to provide (additional) feedstock to make the MFC independent of externally provided feedstock. The skilled person will understand that the variation of the Bioo Panel is another way to obtain this result in a similar way” (para. 100, emphasis added). Thus, the Local Division concluded that a skilled person would therefore understand from the patent that its scope extended beyond the literal claim language to cover equivalent ways of achieving the same core teaching. As such, for the Local Division, the requirement for legal certainty was satisfied.

iv. Is the allegedly infringing product novel and inventive over the prior art?“

The Local Division only briefly addressed this final question, which the Local Division equates to confirming that there is no successfulGillette/Formsteindefence. The Local Division noted that “[a]t the priority date, the Bioo Panel would have been novel and inventive over the prior art because of the introduction of a plant as part of the device as a supplier of additional fuel for the battery/reactor. Parties did not argue otherwise (or differently)” (para. 101). As such, the Local Division found the answer to the question was “yes”. 

The Local Division concluded that that Bioo both directly and indirectly infringed the patent. The Local Division also considered the validity of the patent, finding that it was novel and inventive. The Local Division awarded Plant-e preliminary damages of EUR 35,000 and for Bioo to pay legal costs. 

Final thoughts

The decision in UPC_CFI_239/2023 provides some indication on how the UPC will approach equivalence. The Local Division’s approach represents a relatively patentee-friendly approach to infringement by equivalence. The new four-part test proposed by this Local Division thus appears to set a relatively low bar at the UPC for finding equivalence compared to some national courts, although I would be interested to hear readers views. Of course, there in also plenty of scope for the other divisions of the UPC to develop (or even reject) the test proposed by this Local Division. The decision is merely the first indication of how the UPC may approach this controversial and jurisdictionally variable aspect of patent law. 

Related insights...

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024)

  • 4th December 2025
The global litigation saga involving Amgen’s PCSK9 antibodies has long served as a high-stakes test case for jurisdictional approaches to broad, functionally defined antibody claims. Following the US Supreme Court’s landmark finding of lack of enablement in Amgen v Sanofi, and the UPC Munich Central Division’s initial revocation of the equivalent European patent, all eyes…

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions. 

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.

First use of G 1/24 to broaden clear claim language (T 1849/23)

  • 16th November 2025
This significant decision is the first from the Boards of Appeal to apply G 1/24 to the use of information from the description to broaden otherwise clear claim language.

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.

The unforgiving gold standard: Why deleting a feature can add matter at the EPO (T 0422/23)

  • 30th September 2025
Addition by subtraction: How deleting a feature from a patent claim can fall foul of the EPO’s unforgiving rules on added matter.

The party’s over: EBA leaves late interveners stranded (G2/24)

  • 26th September 2025
Can a third party intervener take over a withdrawn appeal at the EPO? The EBA gives a clear ‘No’.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us